Inventor
Taha MERGHOUB
Inventor
US
Overview
Patents· 25 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C07KPeptides23%
C12NMicroorganisms or enzymes14%
Y02ATechnologies for adaptation to climate change7%
G01NInvestigating or analysing materials by determining their chemical or physical properties6%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms1%
C12YEnzymes1%
G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or protein-related data processing in computational molecular biology1%
PatentTitleYear
12,594,324Methods and compositions for treatment of pancreatic cancer202612,492,257Anti-CTLA-4 antibodies and methods of use thereof202512,397,029Use of MVA or MVADELTAE3L as immunotherapeutic agents against solid tumors202512,331,359Neoantigens and uses thereof for treating cancer202512,252,702Recombinant poxviruses for cancer immunotherapy202512,246,066Anti-CTLA-4 antibodies and methods of use thereof202512,036,279Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors202411,993,653Antibodies and methods of use thereof202411,986,503Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy202411,897,962Anti-GITR antibodies and methods of use thereof202411,884,939Vaccinia virus mutants useful for cancer immunotherapy202411,638,755Anti-CTLA-4 antibodies and methods of use thereof202311,541,087Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy202311,472,883Methods of administering anti-OX40 antibodies202211,447,557Antibodies and methods of use thereof202211,426,460Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors202211,401,335Anti-GITR antibodies and methods of use thereof202211,359,028Anti-OX40 antibodies and anti-GITR antibodies202211,345,755Anti-PD-1 antibodies and methods of use thereof202211,332,536Vectors comprising nucleic acids encoding anti-OX40 antibodies202211,285,209Recombinant MVA or MVADE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors202211,267,889Anti-CTLA-4 antibodies and methods of use thereof202211,253,560Use of MVA or MVADE3L as immunotherapeutic agents against solid tumors202211,242,509Vaccinia virus mutants useful for cancer immunotherapy202211,136,404Anti-OX40 antibodies2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to MEMORIAL SLOAN KETTERING CANCER CENTER (25)· patent assignee history
2021–2025Patents assigned to AGENUS INC (13)· patent assignee history
2021–2025Patents assigned to LUDWIG INST FOR CANCER RES LTD (13)· patent assignee history
2021–2026Based in US· patent location history
2025Patents assigned to ICAHN SCHOOL MED MOUNT SINAI (1)· patent assignee history
2025Patents assigned to LAESSIG MICHAEL (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| MEMORIAL SLOAN KETTERING CANCER CENTER | 25 | 2021–2026 |
| AGENUS INC | 13 | 2021–2025 |
| LUDWIG INST FOR CANCER RES LTD | 13 | 2021–2025 |
| ICAHN SCHOOL MED MOUNT SINAI | 1 | 2025 |
| LAESSIG MICHAEL | 1 | 2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 25 | 2021–2026 |